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ABSTRACT
Transporters comprise the largest family of membrane
proteins in human organism, including members of so-
lute carrier transporter and ATP-binding cassette trans-
porter families. They play pivotal roles in the absorption,
distribution and excretion of xenobiotic and endogenous
molecules. Transporters are widely expressed in various
human tissues and are routinely evaluated during the
process of drug development and approval. Over the past
decade, increasing evidence shows that drug trans-
porters are important in both normal physiology and
disease. Currently, transporters are utilized as therapeu-
tic targets to treat numerous diseases such as diabetes,
major depression, hypertension and constipation. De-
spite the steady growth of the ﬁeld of transporter biology,
more than half of themembers in transporter superfamily
have little information available about their endogenous
substrate(s) or physiological functions. This review out-
lines current research methods in transporter studies,
and summarizes the drug-transporter interactions in-
cluding drug-drug and drug-endogenous substrate in-
teractions. In the end, we also discuss the therapeutic
perspective of transporters based on their physiological
and pathophysiological roles.
KEYWORDS transporter, physiological role, therapeutic
implication
INTRODUCTION
Movement of many drugs and endogenous molecules across
the cell membrane is governed by protein transporters. In
general, membrane transporters are divided into two major
superfamilies—the ATP binding cassette (ABC) family and the
solute carrier (SLC) family. To date,more than 400 transporters
have been annotated in the human genome. The ABC
transporters are primary active transporters that utilize the en-
ergy from ATP hydrolysis to transport substrates across the
membrane. SLCs can be either facilitative transporters, which
transport their substrates down the gradient across the mem-
brane, or secondary active transporters, which transport their
substrates against the gradient across the membrane by cou-
pling a downhill transport of another substrate. Major drug
transporters are listed in Table 1 together with their relevant
abundance among human tissues, physiological roles, en-
dogenous and exogenoussubstrates, and related pathologies.
The biological function of transporters has been investi-
gated using multiple approaches. Among them, metabolomic
studies have been quite valuable for substrate identiﬁcation
of transporters systemically, which identify the alterations of
many metabolites or their substrates directly. Alternatively,
the uptake of substrate candidates can be evaluated by ra-
dio-tracer or radio-free LC/MS quantiﬁcation. This method
was used to identify thiamine and ergothioneine as the
physiological substrates of OCT1 (SLC22A1) and OCTN1
(SLC22A4) respectively (Chen et al., 2014; Gründemann
et al., 2005). Clinically, genome-wide association studies
(GWASs) have proved a powerful method for identifying
disease susceptibility genes. GWASs indicate that genes
coding for a variety of transporters are susceptibility genes
for many diseases (Gottesman and Ambudkar, 2001; Ste-
fková et al., 2004; Grisanzio et al., 2012; Suhre et al., 2011;
Diabetes Genetics Initiative et al., 2007), suggesting that
transporters have important physiological/pathophysiological
roles in disease. The function of transporters in drug ADME
(absorption, distribution, metabolism and excretion) has
been intensively studied during the past two decades but
their physiological roles have been much under studied.
There is emerging evidence that understanding the physio-
logical roles of transporters in normal as well as patho-
physiological conditions is of great value for the development
of new drugs and therapies (the International Transporter
Consortium et al., 2010; Mizuno et al., 2003). In this review,
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we summarize recent progress in the study of physiological
roles of transporters, including new methodology in trans-
porter biology, drug-drug interaction (DDI) and drug-en-
dogenous substrate interaction. Finally, we discuss
pharmaceutical implications of transporters using the roles of
transporters in metabolic diseases as examples.
CURRENT RESEARCH TRENDS IN TRANSPORTER
STUDY
With the rapid progress of biomedical technologies, methods
for studying membrane transporters have expanded exten-
sively. Generally, transporter research methods are per-
formed using bottom-up or top-down approaches. The top-
down approach utilizes computational biology or crystal
structure analyses of transporter structure, which provides
insight into the binding site, binding afﬁnity prediction and the
potential conformational change of the transporter upon
substrate binding. Using this information, predicted agonists
or antagonists for the transporter can be validated via in vitro
transporter assays. The bottom-up approach uses discovery
metabolomics, cell culture and animal models, GWAS or
other genomics data as well as metabolism pathways to
identify substrate candidates for speciﬁc transporters. In this
section, we mainly discuss current trends in methods for
studying membrane transporters.
Structure-based computational biology
Research progress in ligand-protein interaction has been
greatly aided by advances in structural biology, most notably
X-ray crystallography, NMR spectroscopy and electron mi-
croscopy. In particular, computational modeling and virtual
screening of small molecule libraries based on structural
biology have accelerated the identiﬁcation of substrates and
drug candidates of transporters. Although there are only a
few human SLC transporters whose atomic structures have
been determined [e.g. the Rhesus glycoprotein ammonium
transporter SLC42A3 (Gruswitz et al., 2010) and the glucose
transporter SLC2A1 (Deng et al., 2014)], several high-
resolution structures of proteins from prokaryotic and other
eukaryotic organisms are available with at least 25% se-
quence identity with human homologues (Gao et al., 2009;
Fang et al., 2009; Shaffer et al., 2009; Lu et al., 2011).
Substrate prediction and virtual screening of drug candidates
become possible with computational modeling and docking
based on the available structural information. For example,
novel ligands have been successfully screened from com-
pound libraries for the norepinephrine transporter (NET,
SLC6A2, Schlessinger et al., 2011), the GABA transporter 2
(GAT-2, SLC6A13, Schlessinger et al., 2012), and the large-
neutral amino acid transporter (LAT-1, SLC7A5, Geier et al.,
2013), based on the crystal structures of their prokaryotic
homologues. Ligand discovery can also be accomplished by
ligand-based modeling. For example, Wittwer et al. devel-
oped a quantitative structure-activity relationship (QSAR)
model of ligand binding to the multidrug and toxin extrusion
transporter 1 (MATE1, SLC47A1) by experimental high-
throughput screening (HTS) for drug libraries. After reﬁne-
ment by low-throughput experiment validation, the perfor-
mance of the model was improved. The reﬁned model was
then applied to the screening of compound libraries in order
to ﬁnd novel ligands binding to MATE1 (Wittwer et al., 2013).
With the number of resolved membrane transporter struc-
tures increasing and the development of computational
tools, in silico analysis are expected to greatly facilitate
substrate or inhibitor discovery in transporter study.
Clinical genomics
The complexity of human genetics provides a rich resource
to investigate the potential roles of drug transporters in
physiological and pathophysiological conditions. Human
diseases linked to genetic variances, including polymor-
phisms, insertions and deletions, in transporter genes pro-
vide insight into their physiological roles. For example,
ABCG2 was identiﬁed as a renal proximal tubular urate efﬂux
transporter when a GWAS showed that SNPs in ABCG2
were correlated with altered serum urate levels and gout
(Woodward et al., 2009). Further work conﬁrmed that
ABCG2 was a high capacity urate exporter involved in serum
urate homeostasis (Nakayama et al., 2011). Many trans-
porters have multi-speciﬁcity towards numerous substrates
thus the clinical outcomes for transporters like aforemen-
tioned ABCG2 may reﬂect only a portion of their physio-
logical function (Table 1). Mutations in genes that encode
transporter proteins have also been associated with a variety
of human diseases (as shown in Table 1 for drug trans-
porters). For example, genetic defects in glucose trans-
porters like GLUT1 (SLC2A1) have been associated with
glucose-galactose malabsorption (Pascual et al., 2004).
Mutations in anion transporter SLC26 genes are associated
with congenital or early onset Mendelian diseases like
chondrodysplasias, chloride diarrhea and deafness with
enlargement of the vestibular aqueduct (Alper and Sharma,
2013). On the ﬂip side, the identiﬁcation of genetic variants in
transporter genes with protective or beneﬁcial effects pro-
vides substantial therapeutic targets in clinical application.
An example of this is the zinc transporter ZnT8 (see dis-
cussion in the following sections in this review). Information
on genetic variances in transporter genes can be obtained
from a specialized database for transporter pharmacoge-
netics established at University of California, San Francisco
(http://pharmacogenetics.ucsf.edu/). Clinical genomics also
reveal involvement of transporters in bioconversion and
toxicity of drugs. One of the most compelling examples of the
critical role of transporters in drug toxicity stems from a
GWAS encompassing 85 patients with myopathy and 90
normal control individuals (SEARCH Collaborative Group
et al., 2008). This study revealed an association between the
pathology of myopathy and a SNP within a non-coding re-
gion of SLCO1B1 gene. SLCO1B1 encodes the organic
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anion transporting polypeptide (OATP1B1) that has been
shown to be involved in the hepatic uptake of statins.
GWASs have also associated SLCO1B1 and SLCO1B3
variants with bilirubin levels and unconjugated hyperbiliru-
binemia (Johnson et al., 2009; Sanna et al., 2009), reﬂecting
the important function of these transporters in the uptake of
bilirubin in liver. Other GWASs also showed that variants in
SLCO1B1 were associated with reduced clearance of
methotrexate and thus increased gastrointestinal toxicity
(Treviño et al., 2009; Ramsey et al., 2012).
In vitro models
Analysis of the physiological role(s) of a membrane trans-
porter frequently begins with an in vitromodel. Historically, the
Xenopus oocyte has been used as a powerful expression
system to study transporter activity. Due to the limited ex-
pression levels of endogenous membrane transporters,
Xenopus oocytes show little background activity, and thus
provide reliable information with high signal-to-noise ratio
(Bröer, 2010). If combined with high-throughput screening
technology, Xenopus oocytes can even serve as a drug
screening system for certain transporters (Kvist et al., 2011).
Equipment setup for electrophysiology for Xenopus oocytes
and efﬁciency of foreign gene expression, however, are hur-
dles for its further application. More recently human cell lines,
such as HEK-293, CHO and HepaRG cells, have been more
widely used as they have metabolism characteristics that are
similar to the origin tissues and it is easier to express exoge-
nous transporters in cell lines. Moreover, vectorial transport
can be studied in cultured, polarized cells like the Caco-2 and
Madin-Darby canine kidney (MDCK) cells. The colon carci-
noma cell line Caco-2 are especially useful for the study of
intestinal transporters, since these cells exhibit morphological
and functional similarity with the enterocytes lining the small
intestine (Hidalgo et al., 1989). MDCK cells form a tight
monolayer which separates the basolateral and apical sides
similar to cells in biological barriers such as the blood-brain
barrier and the placenta barrier. Such vectorial transport as-
says are important when investigating transport across bio-
logical barriers, from apical to basolateral side or vice versa.
The primary goal of transporter assays is to determine the
kinetics of substrate transport. For the primary active trans-
porter, like the ABC transporter, substrate translocation
across the cell membrane is directly correlated to ATP hy-
drolysis. Thus ATPase assays that measure the inorganic
phosphate release using colorimetric measurement can be
utilized to assess active transporter kinetics (Glavinas et al.,
2007). The ATPase assay is especially useful in high-
throughput screening of substrate candidates as well as
potent inhibitors. ATPase assays, however, are only useful
for a small subset of ABC transporters in which slowly
transported substrates do not stimulate detectable ATPase
activity. Kinetics analysis for most types of ABC transporters
requires whole-cell and vesicle transport assays, as men-
tioned in the following section.
For non-primary active inﬂux transporters, the kinetics can
be measured via uptake assay using intact cells. The accu-
mulation of substrates over a certain period of time can be
quantiﬁed by radio-isotope scintillation counter or LC/MS. The
properties of transporters, however, must be taken into con-
sideration when designing conditions for cellular uptake as-
says. For proton co-transporters, like thoseexpressed in small
intestinal epithelium, optimal transporting activity is usually
observed at acidic pH condition which is close to physiological
conditions in the intestine. The proton-coupled folate trans-
porter (PCFT), encoded by SLC46A1, incorporates folate by
coupling a proton co-transport down the proton gradient at pH
5.5, however, this transport activity is absent at neutral pH
(Nakai et al., 2007). Peptide transporters 1 and 2 (PEPT1 and
PEPT2, encoded by SLC15A1 and SLC15A2) are similar
examples, which mediate absorption small peptides and
peptide-like drugs from the intestine and kidney respectively
with symport of a proton (Liu et al., 1995; Liang et al., 1995).
There are also examples of sodium symporters whose activity
relies on sodium gradient. The transport activity of such
transporters, like SLC10A1, SLC10A2, SLC22A4 and
SLC34A1, can be greatly suppressed when the sodium ions
are replaced by choline (De Bruyn et al., 2011).
Isolated cell membranes are another reliable method to
investigate transporter activity. Membranes can be prepared
from insect cells, mammalian cell lines, or primary cells in
which the transporter of interest is overexpressed. Insect
cells like Sf9 and Sf+ are widely used because of high
membrane yields and easy culturing. The major drawback of
insect cells is that their cholesterol content is signiﬁcantly
lower than that of mammalian cells. Membrane cholesterol
contributes to transporter activity, especially in the ABC
transporters (ABCB11, Kis et al., 2009; ABCC2, Ito et al.,
2008; ABCG2, Pal et al., 2007). Thus supplementation of
cholesterol is sometimes necessary when using membranes
extracted from insect cells. For efﬂux transporters, direct
measurement of the substrate translocation can be achieved
by a vesicular transport assay. Enriched, inside-out mem-
branes are prepared using commercially available kits and
incubated with the substrate and ATP or the appropriate
energy source for the transporter of interest. After ﬁltration,
the vesicles containing the substrates are captured, which
allows for quantiﬁcation of the substrates inside vesicles via
radio-isotope scintillation counter or LC/MS.
In vivo models
Todate,mice and rats serve as themost relevant in vivomodel
for the ﬁeld of transporter biology. The recent emergence of
zinc-ﬁnger nuclease (ZFN), TALEN and CRISPR/Cas-based
genomic engineering provides powerful and convenient tools
to generate transgenic or knockout animals for a gene of in-
terest (Gaj et al., 2013). Beyond traditional overexpression or
knockout in the whole body, tissue speciﬁc or local modiﬁca-
tion can also be achieved through ﬂoxP-Cre or Tet-on/off ex-
pression systems. Moreover, overexpression and knockdown
REVIEW Yu Liang et al.









locally in a certain tissue or at a speciﬁc developmental point
can be achieved bymicroinjection of gene expression vectors
followed by electronic transfection. Animal models are a
powerful tool to study the physiological function of a trans-
porter. Systemic overexpression or knockdown of a trans-
porter can produce phenotypes that provide information about
tissue speciﬁc functions. Some transporters are enriched in
certain tissues implying that they have unique physiological
functions. Thus alteration of transporter activity through ge-
netic means may only be observed locally within a speciﬁc
tissue and possibly, loss of transporter expression may be
compensated by its functional orthologues or homologues.
The LC/MS based metabolomics may help characterizations
of local metabolite changes caused by transporter deletion or
overexpression in a speciﬁc tissues or circulating system. For
example, tissue extracts from liver or muscle can be used to
investigate the role of a transporter in energy related meta-
bolism; urine and serum can be used to study alterations in
secreted or excreted metabolites.
DRUG-TRANSPORTER INTERACTIONS
Drug-drug interactions
Due to the critical roles of transporters in the ADME of drugs,
a variety of drug transporter assays are required by both
FDA and EMA prior to testing of a New Chemical/Molecular
Entity (NCE/NME). Potential drug-drug interactions (DDIs)
may cause severe, adverse reactions in patients due to al-
teration in ADME by transporters. Most DDIs via transporters
involve, but are not restricted to, the main transporters in
drug ADME: P-gp, BCRP, OATP1B1/1B3, OAT1/3, OCT1
and OCT2 (Tweedie et al. 2013). The International Trans-
porter Consortium has established decision trees for inves-
tigating the transporter interactions of drugs (International
Transporter Consortium et al., 2010).
DDIs via a transporter can also occur in an indirect
manner. The expression level and transporting activity of
transporters may be altered as part of the systemic response
(i.e., immune response) to exogenous or endogenous stim-
uli. Altered drug ADME during inﬂammation has long been
primarily ascribed to changes of enzymes in drug metabo-
lism. An example of this is decreased expression of P450,
the main drug metabolizing enzyme in liver, following in-
ﬂammation. Moreover, recent studies have also shown that
the expression and activity of numerous transporters are
also changed in inﬂammatory condition. In experimental cell
and animal models, inﬂammatory conditions induced down
regulation of MDRs, MRPs and OATPs. Consequently, the
ADME of drugs which are substrates of these transporters
would be broadly affected (Petrovic et al., 2007).
Drug-endogenous substrate interactions
Although DDIs via transporters have been widely studied,
the interaction between drugs and endogenous substrates
has not received signiﬁcant attention. The transportation and
distribution of many endogenous substrates like hormones,
bile acids and neurotransmitters mainly depend on the ac-
tivity of transporters.
The most well-known case of drug-endogenous substrate
interaction is the drug induced liver injury (DILI) due to
cholestasis. The transporter BSEP plays an important role in
the disposition and exportation of bile salts from liver. BSEP
inhibition by drugs can cause accumulation of bile salts in
liver, thus leading to cholestasis. There is a strong correla-
tion between inhibition of the in vitro efﬂux transporter activity
of BSEP and the risk of cholestatic DILI (Dawson et al.,
2012). BSEP was thought to be the primary bile acid efﬂux
transporter in normal conditions in humans (Kis et al., 2012),
while MRP3 and MRP4 may play compensatory roles when
BSEP is impaired (Keppler, 2011). A recent study regarding
the relationship between MRP3, MRP4 and BSEP inhibition
and drugs with cholestatic potential showed that inhibition of
MRP4, in addition to BSEP, might be a risk factor for the
development of cholestatic DILI, while the inhibition of MRP3
seemed not statistically signiﬁcantly associated (Köck et al.,
2014). The EMA has already included a test of BSEP
transporter for potential liver toxicity.
Substrate multi-speciﬁcity of transporters and/or low
amount of substrates makes altered transport of an en-
dogenous substrate difﬁcult to identify. Local changes in
substrate homeostasis, however, may become obvious un-
der pathological conditions. This can be due to the changes
of transporter expression level under pathological conditions
or because of an individual taking certain drugs. Recently it
was reported that the drugs metformin and phenformin
competitively inhibited hepatic thiamine uptake via OCT1, a
high-capacity thiamine transporter in liver, to modulate the
energy status in hepatocytes (Chen et al., 2014). OCT1 is
the major hepatic uptake transporter for xenobiotics, in-
cluding the most prescribed anti-diabetic drug metformin and
anti-cancer drug oxilaplatin (Shu et al., 2007; Wang et al.,
2002; Li et al., 2011). It has been proposed that together with
drug-metabolizing enzymes, OCT1 contributes mainly to the
detoxiﬁcation pathway of liver (Zhang et al., 2006). But the
exact physiological role of OCT1 remained speculative.
Using metabolomic analysis of OCT1 overexpressed in
HEK293 cells and isotopic uptake assays, thiamine was
identiﬁed as one substrate, with low-afﬁnity but high-capacity
to OCT1 (Chen et al., 2014). The Oct1 KO mice provide a
model to investigate the function of Oct1 systemically. Thi-
amine is converted to thiamine monophosphate (TMP) and
thiamine pyrophosphate (TPP) in cytosol, which serves as
the essential co-enzyme for energy generation and glucose
metabolism. Due to reduced thiamine uptake in liver, thi-
amine-related changes were observed in the serum of Oct1
KO mice. These included reduced levels of TMP and TPP
and higher levels of pyruvate and alpha-ketoglutarate, which
are the substrates of pyruvate dehydrogenase (PDH) and
alpha-ketoglutarate dehydrogenase (OGDH) (Chen et al.,
2014), respectively. SLC19A2 (Labay et al., 1999; Diaz et al.,
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1999) and SLC19A3 (Rajgopal et al., 2001) are high-afﬁnity
thiamine transporters; however, OCT1 is likely the primary
transporter for thiamine uptake in the liver. This is supported
by the drastic reduction of thiamine uptake in Oct1 deﬁcient
mouse primary hepatocytes (Chen et al., 2014). Oct1 deﬁ-
ciency does not lead to obvious outcomes in other tissues
where the uptake of thiamine is possibly controlled mainly by
SLC19A2 or SLC19A3.
OCT1 has also recently been shown to be a transporter
for monoamine neuro-transmitters (serotonin, dopamine,
epinephrine and norepinephrine) and OCT1 might play a
critical role in the uptake of serotonin in liver (Boxberger
et al., 2014). The monoamine uptake transporter SERT is
widely expressed in the gut where the monoamine trans-
mitters have important physiological functions. Though liver
is the major organ in which serotonin is metabolized, SERT
is not expressed in liver (Ramamoorthy et al., 1993). Com-
mon OCT1-transported drugs including diphenhydramine,
ﬂuoxetine, imatinib and verapamil were shown to inhibit
hepatic serotonin uptake with IC50 values in the low micro-
mole range (Boxberger et al., 2014). The reduction of sero-
tonin uptake in Oct1 deﬁcient primary hepatocyte was only
28% indicating that there are other transporters which con-
tribute to the uptake of serotonin in liver (Chen et al. 2014).
OCT3 and PMAT are possibly candidates as both are high-
capacity serotonin transporters (Wu et al., 1998; Zhou et al.,
2007); however, both have low abundance in the liver
compared to OCT1. Another explanation could be that these
drugs not only block OCT1 but also other transporters-me-
diating serotonin uptake in the liver.
The drug-endogenous substrate interaction has also
been investigated in the kidney efﬂux transporters MATEs.
Pyrimethamine, a commonly used anti-protozoal drug for
both the prevention and treatment of malaria, inhibits the
renal clearance of thiamine, carnitine and acylcarnitine by
about 80%, 90% and 90% respectively in urine samples from
patients. Nonetheless, plasma concentrations of the afore-
mentioned compounds are not changed. Thus, alterations of
thiamine and carnitine in the urine are thought to be useful as
biomarkers in evaluating drug interactions via MATEs (Kato
et al., 2014).
EMERGING ROLE OF TRANSPORTERS
AS THERAPEUTIC TARGETS
Acting as the “gatekeepers” for the ADME of drugs and
endogenous substrates including hormones, glucose, amino
acids, inorganic ions, neurotransmitters and cellular
metabolites, transporters have drawn increasing attention for
drug development in recent years. Transporter-mediated
therapeutics is achieved via stimulation or inhibition of the
substrate transporting activity or potential cellular signaling
involved. More than a dozen transporters have already been
targeted in clinical therapy. These include the monoamine
transporters for treatment of mental disorders like depres-
sion and schizophrenia, SGLT2 for treatment of diabetes and
the MDR and MRP transporters in cancer therapy. However,
much remains to be uncovered as the physiological func-
tions of many transporters are still largely unknown. The
physiological roles of transporters are generally consistent
with their distribution in the body, i.e. the tissue speciﬁc ex-
pression. For example, OCT1 is mainly expressed in the
central vein of liver where its physiological function is to
uptake thiamine into hepatocytes (Chen et al., 2014). Most of
the known functions of transporters involve inward and out-
ward transportation of substrate across the plasma mem-
brane. There are also transporters, however, which localize
in the nuclear envelope and membranes of other organelles
like the mitochondria, the lysosome, the endoplasmic reti-
culum and the Golgi apparatus. Investigating the physio-
logical function of transporters is important not only for
understanding the nature of substrate transportation but also
for the seeking of new therapeutic targets. In this section we
discuss three transporters that are potentially involved in the
pathology of diabetes as examples of how a transporter’s
physiological function has therapeutic implications.
The thiamine transporter OCT1
OCT1 controls the liver uptake of thiamine whose derivative
TPP serves as the essential cofactor in energy generation.
The loss of Oct1 in mice results in a 70% reduction in thi-
amine uptake in liver and signiﬁcantly reduced fat accumu-
lation in both lean and obese mice. This indicates that OCT1
may be a promising therapeutic target in the treatment of
non-alcoholic fatty liver disease for which there are few ef-
fective therapies (Halegoua-De Marzio and Fenkel, 2014).
Metformin, the most prescribed anti-diabetes drug, inhibits
OCT1-mediated thiamine uptake, which corresponds well to
the physiological role of OCT1 (Chen et al., 2014). This
ﬁnding not only uncovered part of the pharmacological effect
of metformin but also provides new therapeutic insight in the
treatment of diabetes. An intriguing possibility is that by
regulating the uptake of thiamine by hepatocytes, it is pos-
sible to alter the energy status in the liver and thus regulate
the homeostasis of gluconeogenesis and glycolysis in
diabetic patients.
The citrate transporter SLC13A5
InDrosophila, loss of INDY (I’mNot DeadYet), the homologue
of mammal SLC13A5, confers extended lifespan in a caloric
restriction-like manner (Rogina et al., 2000) with reduced
whole body fat stores and expression of insulin like proteins
(Wang et al., 2009). SLC13A5 mediates the uptake of citrate
into cytosol across the plasmamembranewith high speciﬁcity.
Analyses of the structure of bacterial Indy reveal a conserved
substrate binding region across a wide range of species
(Mancusso et al., 2012). As one of the main intermediates in
theTCAcycle, citrate also regulates fatty acid synthesis andβ-
oxidation (Fig. 1). Hence, SLC13A5 may serve as a potential
therapeutic target in the treatment of metabolic disorders
REVIEW Yu Liang et al.









including non-alcoholic fatty liver disease, obesity and dia-
betes. Consistent with this, loss of Slc13a5 in mice results in
reduction in the liver uptake of citrate from circulation
accompanied by an increase inmitochondrial biogenesis, lipid
oxidation, energy expenditure and decrease in hepatic de








































Figure 1. Cartoon illustration of the physiological roles and therapeutic implications of OCT1, SLC13A5 and ZnT8 in glucose
metabolism, lipogenesis and insulin pathway. Inhibition of OCT1 (e.g., metformin treatment) results in lowered hepatic thiamine
uptake, and consequently reduced TPP levels. The reduced ATP production, due to the decreased PDH and OGDH activity, triggers
AMPK activation. The inhibition of SLC13A5 leads to lowered cytosol citrate contents, which attenuate the activating effect of citrate in
malonyl-CoA synthesis. Both OCT1 and SLC13A5 inhibition reduce TG synthesis in the liver. Inhibition of ZnT8 causes reduced zinc
release from the β-cell, and thus attenuates the autocrine effect of zinc in glucose induced insulin production; the hepatic zinc content
is also reduced, with concomitant increased insulin clearance. The effects of OCT1, SLC13A5 and ZnT8 inhibition are shown with
red, yellow and blue arrows respectively.
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high-fat diet inducedobesity and insulin resistance (Birkenfeld
et al., 2011). Currently, there is no available drug that
speciﬁcally modulates SLC13A5 activity. Some compounds
have been reported as selective inhibitors of the plasma
membrane citrate transporter for both mammalian SLC13A5
and the Drosophila INDY, leaving mitochondria citrate trans-
porter activity unchanged (Sun et al., 2010). A recent study
reported the crystal structure of VcINDY, a homologue of
SLC13A5 in Vibrio cholera at 3.20 Å. This provides the
structural basis for understanding the substrate binding
properties as well as conformational change upon substrate
binding (Mulligan et al., 2014). Together with computational
biology, the development of drugs targeting the SLC13A5
could be accelerated for potential therapeutics of carbohy-
drate and lipid metabolism disorders like diabetes, non-alco-
holic fatty liver and obesity.
Zinc transporter ZnT8
Zinc transporters are reported to be involved in the patho-
physiology of cancer, cardiovascular diseases and Alzhei-
mer’s disease making them possible therapeutic targets for
treatment of these diseases (Prasad et al., 2009; Little et al.,
2010; Watt et al., 2011). Normal cellular function requires
tightly controlled zinc homeostasis through coordinated ac-
tions of zinc transporters and metallothioneins. Emerging
evidences suggest that zinc transporters are also involved in
that pathology of diabetes mellitus. Zinc plays key roles in
the synthesis, storage and secretion of insulin in response to
elevated glucose concentrations (Mocchegiani et al., 2008;
Wijesekara et al., 2009). Of particular relevance to diabetes
is the most well studied zinc transporter ZnT8 (SLC30A8).
ZnT8 is responsible for the packaging and storage of insulin
as Zn2+-insulin hexamers in the secretory granules of the
pancreas, which releases the physiologically active form of
insulin in the serum driven by a pH change (Xu et al., 2012b).
The relationship between ZnT8 and diabetes risk has been
veriﬁed in cultured cells as well as in mice. In a pancreatic
cell line INS-1, ZnT8 overexpression showed enhanced
glucose-stimulated insulin secretion (Chimienti et al., 2006)
while down regulation of this transporter leads to reduced
insulin production in response to a hyperglycemic stimulus
(Fu et al., 2009). Knockout mice with global deﬁciency of
ZnT8 showed normal glucose homeostasis and insulin pro-
duction under normal conditions (Lemaire et al., 2009).
Glucose tolerance and glucose-induced insulin secretion are
impaired when challenged with a high-fat diet and these
mice further develop diabetic obesity and insulin resistance
(Lemaire et al., 2009; Nicolson et al., 2009). Mutant mice
with a targeted beta cell ZnT8 deﬁciency display glucose-
intolerance, reduced beta cell zinc accumulation and in-
creased proinsulin levels when fed with high-fat diet, indi-
cating the deﬁciency in insulin processing and secretion.
These mice, however, do not develop obesity (Wijesekara
et al., 2010). Genetic studies in humans also support a
correlation between ZnT8 and diabetes risk. Several
GWASs revealed genetic association between ZnT8 and
diabetes onset (Sladek et al., 2007; Xu et al., 2012a; Dia-
betes Genetics Initiative et al., 2007). The most compelling
evidence comes from a common SNP rs13266634
(c.973T>A, p.Trp325Arg) in Europeans which increased the
risk of developing type II diabetes with concomitant impaired
conversion of proinsulin to insulin (Sladek et al., 2007 and
Kirchhoff et al., 2008). Cellular experiments show that the
Arg325 ZnT8 variant exhibits lower apparent Zn2+ transport
activity than the Trp325 ZnT8 (Nicolson et al., 2009). Col-
lectively these studies indicated that reduced Zn transport
activity by ZnT8 is connected to the diabetes risk. Thus
treatments that increase ZnT8 transport activity might be a
novel therapeutic route for treatment of diabetes.
The exact relationship between ZnT8 activity and dia-
betes risk, however, remains controversial. Zn ions have
several effects on the regulation of insulin production and
clearance. Co-secretion of Zn ions with insulin from beta
cells inhibits insulin production in an autocrine and paracrine
fashion through the K-ATP channel (Bancila et al., 2005;
Prost et al., 2004). Beta cell-secreted Zn ions also regulate
hepatic clearance of insulin. A recent study showed that
beta-cell speciﬁc deﬁciency of ZnT8 results in low peripheral
insulin level but hypersecretion of insulin from pancreas
(Tamaki et al., 2013). Further, ZnT8 deﬁcient mice and hu-
mans with the Trp325Arg ZnT8 variant exhibit increased
insulin clearance. This in turn stimulates the secretion of
insulin by pancreas and increases susceptibility to devel-
oping type II diabetes (Tamaki et al., 2013).
Intriguingly, a recent GWAS reported that 12, rare trun-
cating mutations in ZnT8 were surprisingly protective against
developing diabetes and, collectively, explained a 65% re-
duction in diabetes risk (Flannick et al., 2014). Although their
study was originally performed in the European population
with SNP rs13266634 genetic background, it was shown that
this haplotypic background did not inﬂuence the conclusion
(Flannick et al., 2014). Though the exact mechanism re-
mains elusive, the size of the GWAS data pool (∼150,000
individuals across ﬁve ancestry groups) legitimizes the
ﬁnding. A recent review of the paper pointed to the unclear
association between increased insulin receptor binding and
liver insulin action with lower concentration of Zn ions
(Pearson, 2014). Clearly, the roles of ZnT8 in Zn home-
ostasis and diabetes are more complicated than expected.
On the one hand, ZnT8 is essential for insulin processing
and secretion in response to glucose challenge thus total
loss of its function causes glucose-intolerance. On the other,
secreted Zinc ions into liver portal vein indeed regulate the
gluconeogenesis and insulin pathway in hepatocytes. The
GWAS by Flannick et al. reveals an alternate view of ZnT8
and diabetes risk. Different from OCT1 and SLC13A5, which
show local control of carbohydrate and lipid metabolism in
the hepatocytes, ZnT8 shows a systemic regulation of insulin
pathway in the pancreas and liver (Fig. 1). Thus, drug can-
didates that act on ZnT8 would be expected to be potent
novel anti-diabetes therapeutics.
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SUMMARY AND FUTURE PERSPECTIVES
Transporter biology is a rapidly changing ﬁeld in pharmaceu-
tical research. Identifying the function of transporters in
physiological and pathological conditions is garnering sig-
niﬁcant attention for drug development. Many drugs, nutrients
and metabolites are moved by transporters not only through
the plasma membrane but also among subcellular organelles
like vesicles, ER, lysosome and mitochondria. Transporters
remain one of the most underestimated ﬁelds for drug targets.
Within the hundreds of annotated transporters in human
genome,more thanhalf are orphan transporterswith unknown
substrates or function. The nature of these transporters, in-
cluding their expression and localization in organs and tis-
sues, subcellular localization, endogenous substrates, largely
remains elusive. As discussed in this review, transporters can
be of signiﬁcant therapeutic potential in the treatment of var-
ious diseases. A comprehensive dissection of the physio-
logical roles of the transporter could be a key step to excavate
this “goldmine”. Our growing knowledge of transporter biology
will greatly accelerate the discovery of novel drug targets and
development of ﬁrst-in-class therapies.
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